Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
08 Aug 2016
Positive efficacy data from a compassionate use clinical trial in Burns released by Amarantus BioScience
08 Aug 2016
Clinical trials in Burns (In children) in USA (Topical) prior to August 2016
http://adisinsight.springer.com/drugs/800041714
PRORATA SHARE OF ASSETS CSC TRUST
https://www.kccllc.net/wmitrust/document/8817600120507000000000002
On the Statement of Net Assets, as of March 31, 2012, specific DCR assets include cash of $722.6 million and Runoff Notes (including
interest) of $1.2 million. Furthermore, the DCR owns a prorata share of the remaining assets of the Trust. Assets of the DCR will be made
available to the LTI holders in accordance with the Plan should disputed claims become disallowed. For further information regarding the
DCR, see the “Rollforward of Liquidating Trust Interests” and the “Rollforward of Disputed Claims Reserve”.
Debtors never denied 33B assets raised by EC.EC said so in the court that there was no objection from the Debtor about the 33B assets.That was the reason it was never contested in the court.
JPM bought assets of WMI under the plan and GSA.Where is that money residing?.Who will get that money?.Escrows imho.
Read equity committee objection of POR 6.
After DB & JPM Indeminity claims resolution
Now comes the unsecured creditors in the receivership claims process
Next comes the equity claims.
Washington Mutual Litigations. Proceedings related to Washington Mutual’s failure are pending before the United States District Court for the District of Columbia and include a lawsuit brought by Deutsche Bank National Trust Company, initially against the FDIC and amended to include JPMorgan Chase Bank, N.A. as a defendant, asserting an estimated $6 billion to $10 billion in damages based upon alleged breaches of certain representations and warranties given by certain Washington Mutual affiliates in connection with mortgage securitization agreements. The case includes assertions that JPMorgan Chase Bank, N.A. may have assumed liabilities for the alleged breaches of representations and warranties in the mortgage securitization agreements. In June 2015, the court ruled in favor of JPMorgan Chase Bank, N.A. on the question of whether the Firm or the FDIC bears responsibility for Washington Mutual Bank’s repurchase obligations, holding that JPMorgan Chase Bank, N.A. assumed only those liabilities that were reflected on Washington Mutual Bank’s financial accounting records as of September 25, 2008, and only up to the amount of the book value reflected therein. The FDIC is appealing that ruling and the case has otherwise been stayed pending the outcome of that appeal.
JPMorgan Chase has also filed complaints in the United States District Court for the District of Columbia against the FDIC, in its corporate capacity as well as in its capacity as receiver for Washington Mutual Bank, asserting multiple claims for indemnification under the terms of the Purchase & Assumption Agreement between JPMorgan Chase Bank, N.A. and the FDIC relating to JPMorgan Chase Bank, N.A.’s purchase of substantially all of the assets and certain liabilities of Washington Mutual Bank (the "Purchase & Assumption Agreement").
The Firm, Deutsche Bank National Trust Company and the FDIC have signed a term sheet to resolve (a) pending litigation brought by Deutsche Bank National Trust Company against the FDIC and JPMorgan Chase Bank, N.A., as defendants, relating to alleged breaches of certain representations and warranties given by certain Washington Mutual affiliates in connection with mortgage securitization agreements and (b) JPMorgan Chase Bank, N.A.’s outstanding indemnification claims pursuant to the terms of the Purchase & Assumption Agreement. The term sheet is subject to FDIC Board approval, finalization of settlement documents and certain judicial approval procedures.
https://www.sec.gov/Archives/edgar/data/19617/000001961716001056/corpq22016.htm
W-9 was submitted during the voting,remember?
I am a pre and post shareholder.But it does n't really matter because all shares were authorized and issued before 9/25/2008.
RESTRICTED & Unrestricted CASH
Distribution of Liquidating Trust Assets
The Liquidating Trustee shall distribute to the holders of Allowed Claims on account of
their Liquidating Trust Interests, on a quarterly basis, all unrestricted Cash on hand (including any Cash
received from the Debtors on the Effective Date,
Notes:
(a) Cash is comprised of cash (including WMI’s share of Tax Refunds already received) and
restricted cash at WMI, WMI Investment Corp., plus payments from JPMC for Visa Shares and
intercompany loans pursuant to the Global Settlement Agreement proceeds related to the
American Savings Bank Goodwill Litigation, including the recently awarded Warrant Award, and
BOLI/COLI and Rabbi Trust assets in both chapter 7 and 11 cases.
Where is this RESTRICTED CASH and what is it doing,bk?
Click on Washington Mutual Bank Purchase and Assumption Agreement -
https://www.fdic.gov/about/freedom/readingroom.html
Signatures on page 38/44 are overwritten with yellow boxes.???Something getting closer?
FDIC showing latest P&A with a date 7/15/16, i dont know why.
www.fdic.gov search "washington mutual" sort by date.
This phoney cfo leaving due to the joint venture about to happen?.This is the guy with help from Gerald brought the toxic financing into iambs?
ESS Joint Venture & Army Trials
Just before a long weekend,huh?
On June ?27, 2016, the Company’s contract manufacturer for its Engineered Skin Substitute ("ESS" or "Permaderm(tm)") program notified the Company’s management of the need to perform retraining of key personnel prior to opening the Phase 2 clinical study with the U.S. Army. The retraining is expected to take approximately 3-5 weeks.
On June 30, 2016, the Company entered into a non-binding Letter of Intent (the "LOI)? with a commercial-stage wound-care company to form a joint venture (the "JV") for the further development of the Permaderm program. Under the terms of the LOI, the parties have exclusivity of negotiations for a period 30 days to enter into definitive agreements as it relates to the JV (the "Exclusivity Period"). The Exclusivity Period may be extended upon mutual consent of the parties.
https://www.sec.gov/Archives/edgar/data/1424812/000121390016014658/f8k062716_amarantusbio.htm
Oh really?. First let them expunge the claims and think of cancelling .
May be some convertible preferred shares exchanged?.
REVERSED AND REMANDED - JPM transferring a note when the original was missing...
Foreclosure/Standing: plaintiff failed to establish standing at time foreclosure filed where original note never filed with court and no other evidence of possession presented to court - Cruz v. JPMorgan Chase Bank, National Association, as Successor in Interest to Washington Mutual Bank, formerly known as Washington Mutual Bank, F.A., No. 4D14-3799 (Fla. 4th DCA June 15, 2016) (reversed and remanded)
https://www.lexology.com/library/detail.aspx?g=e41fa3ec-893b-473c-afd3-a89ab04a1869
Firing from AMBS, CEO,CFO,Jruben and CEOs dad
Wont get a response.May be, is stuck just like me.
And what merger you are talking about?
This is for LHHMQ and we are in LEHNQ.Why the claims are not EXPUNGED?
Why the CT claims are allowed and not expunged?.Dont they have to Expunge the claims inorder to cancel the securities?.
Classes 3 to 5 need to be satisfied 100% inorder to get any distributions to classes 10A,10B and 10C.
Record date May 18 2016?
Why did they set a record date for the distribution s on June 16?
Are the claims still trading?.
Are these claims CTs?
I did not send any forms for Cts as aquired them after the plan approval.I sent some information for my JQs and DQs.
I do own Nqs,Kqs,Jqs.
If i dont own any, why would i even be on this forum?.
JPM Getting around 1.49B in 10th distribution, does CTs get any thing?.
Did any of CT holders complete OFAC and tax forms?
http://www.businesswire.com/news/home/20160609005612/en
cGMP was one of those milestones as per the below press release
Dec 22,2015
Amarantus Provides Update on cGMP Manufacturing Validation for the Engineered Skin Substitute (ESS) Program
SAN FRANCISCO, Dec. 22, 2015 /PRNewswire/ -- Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today provided an update on the status of its current manufacturing process validation for producing ESS at Lonza Walkersville, a premier contract manufacturer providing cell- and tissue-based products for clinical development. Ongoing engineering run activities are progressing successfully, and Amarantus expects to complete the necessary steps to confirm the process in January. Upon completing the validation studies, Amarantus will be ready from the operational perspective to open the planned Phase 2 clinical study for the treatment of full thickness thermal burns covering over 50% of the body. The trial is being conducted under a Collaborative Research & Development Agreement (CRADA) with the U.S. Army at the Institute for Surgical Research at Fort Sam Houston in Texas.
Milestones towards validation are as follows:
Aseptic process simulation execution and qualification of the process and personnel used in manufacturing:
Completed in November 2015
Initial engineering run whereby autologous full thickness skin from an adult human donor is produced:
Completed in December 2015
Confirmatory engineering run whereby autologous full thickness skin from an adult human donor is produced:
In progress - Expected completion in January 2016
"Validating the manufacturing process for ESS is the key operational milestone at this point on the program's path towards commercialization," said Gerald E. Commissiong, President & CEO of Amarantus. "Working with an established contract manufacturer, we will be operationally enabled to open up the 10 patient Phase 2 clinical study under our CRADA with the US Army's ISR, and we will also be in a position to initiate discussions with the FDA on trial designs for evaluating ESS in Giant Congenital Melanocytic Nevi (GCMN) and pediatric severe burn indications. We believe ESS may be eligible to achieve Rare Pediatric Disease Designation (RPDD) for both of these indications, and our regulatory team is now focused on submitting the request for RPDD for the treatment of GCMN to the U.S. FDA by the end of 2015, with a decision in the first quarter of 2016. Given that it is estimated GCMN affects a very small pediatric population, (between 8 and 80 newborns annually in the U.S), we anticipate a potentially rapid product approval pathway with the pivotal program anticipated to initiate in the second half of 2016."
The FDA defines a "rare pediatric disease" as a disease that affects fewer than 200,000 individuals in the U.S. primarily aged from birth to 18 years. Under the FDA's Rare Pediatric Disease Designation (RPDD) Priority Review Voucher (PRV) program, a sponsor who receives an approval of a new drug application (NDA) or biologics license application (BLA) for a rare pediatric disease may be eligible for a voucher, which can be redeemed to obtain expedited FDA review for any subsequent marketing application. The PRV may be sold or transferred by the recipient. The two most recent PRVs that were sold garnered a combined $595M in cash from Sanofi and Abbvie.
About Giant Congenital Melanocytic Nevus
Giant Congenital Melanocytic Nevus, a rare pediatric condition (also known as "Bathing trunk nevus," "Garment nevus," "Giant hairy nevus", and "Nevus pigmentosus et pilosus"), is defined by one or more large, darkly pigmented and sometimes hairy patches. The congenital (present at birth) melanocytic nevus appears as a circumscribed, light brown to black patch, potentially varying in consistency, covering any size surface area and any part of the body. As compared with melanocytic nevi that arise after birth, congenital melanocytic nevi are usually larger in diameter and may have excess hair, a condition called hypertrichosis. The estimated prevalence for the largest melanocytic nevi is 0.002% of births in the US. A serious risk factor for the largest CMN concerns the incidence of melanoma, which can be up to 10%. Generally, melanoma in patients with large to giant CMN occurs within the first decade of life with the greatest incidence rate before age 5 and has a high fatality rate. A second life-threatening complication of the larger forms of CMN is neurocutaneous melanocytosis (NCM), a neurological and dermatological disorder characterized by abnormal cellular aggregations within the central nervous system and the skin. The incidence of NCM ranges between 5 and 15 % in this CMN patient subset; death usually occurs within 2-3 years of diagnosis of symptomatic NCM.
About Engineered Skin Substitute (ESS)
Engineered Skin Substitute (ESS) is a tissue-engineered skin prepared from autologous (patient's own) skin cells. It is a combination of cultured epithelium with a collagen-fibroblast implant that produces a skin substitute that contains both epidermal and dermal components. This model has been shown in preclinical studies to generate a functional skin barrier. Most importantly, because ESS is composed of a patient's own cells, it is less likely to be rejected by the immune system of the patient, unlike with porcine or cadaver grafts in which immune system rejection is a possibility. ESS has been used in an investigator initiated clinical setting in over 130 human subjects, primarily pediatric patients, for the treatment of severe burns up to 95% total body surface area.
June 07,2016
Amarantus Announces cGMP Manufacturing Readiness for Its Engineered Skin Substitute (ESS) Program at Lonza Walkersville
Amarantus-sponsored training for Phase 2 severe burn trial completed with U.S. Army clinical site in late April
SAN FRANCISCO, June 7, 2016 /PRNewswire/ --
Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that the current Good Manufacturing Practices (cGMP) manufacturing process for its Engineered Skin Substitute (ESS) program is now qualified at Lonza Walkersville, Inc., a premier contract manufacturer providing cell and tissue-based products for clinical development. ESS is a lab-grown, full-thickness skin graft made from a patient's own skin that is expanded ~100 fold in size to provide permanent wound coverage of large body surface areas, initially for use in treating life-threatening burns.
Reaching this milestone signifies that Amarantus is now positioned to supply ESS for its planned opening of the 10-patient, randomized, placebo-controlled, open-label Phase 2 clinical trial for the treatment of adult patients (ages 18-40 years old) with deep-partial and full-thickness thermal burns covering ≥50% of total body surface area (TBSA). The Company will open enrollment at the first site, the U.S. Army's Institute for Surgical Research (ISR) at Fort Sam Houston in Texas, under a Collaborative Research & Development Agreement (CRADA). Two additional civilian sites will be opened after ISR to accelerate enrollment of the study.
The Phase 2 clinical trial is designed to measure the safety and comparability of ESS with meshed split-thickness autografted skin, the current standard of care in the treatment of life-threatening severe burns. Amarantus will be reporting pre-defined data points on an ongoing basis throughout the trial on a patient-by-patient basis.
"cGMP-readiness at Lonza marks the first of several major milestones for the ESS program," said Gerald E. Commissiong, President & CEO of Amarantus. "Amarantus performed the sponsor portion of the site initiation process at ISR in late April, and the site is completing its final preparations to initiate the study. We expect the remaining items to be completed soon, at which point we will open enrollment for this breakthrough regenerative medicine cell therapy trial at the US Army's premier surgical research center."
About Engineered Skin Substitute (ESS)
Engineered Skin Substitute (ESS) is a tissue-engineered skin prepared from autologous (patient's own) skin cells. It is a combination of cultured epithelium with a collagen-fibroblast implant that produces a skin substitute that contains both epidermal and dermal components. This model has been shown in preclinical studies to generate a functional skin barrier. Most importantly, because ESS is composed of a patient's own cells, it is less likely to be rejected by the immune system of the patient, unlike with porcine or cadaver grafts in which immune system rejection is a possibility. A non-GMP version ESS has been used in investigator-initiated and compassionate-use clinical settings in over 150 human subjects, primarily pediatric patients, for the treatment of severe burns up to 95% of total body surface area. The non-GMP version has also been used in the treatment of two patients with Giant Congenital Melanocytic Nevi (GCMN). The Company is evaluating opportunities to launch a pivotal clinical study with ESS in the areas of GCMN and pediatric severe burns once experience is gained in the adult severe burn setting.
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases. AMBS acquired the rights to the Engineered Skin Substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture. ESS is entering Phase 2 clinical studies under a CRADA agreement with the US Army. AMBS has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, adult ADHD and Alzheimer's aggression, and owns the intellectual property rights to a therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor (MANF) and is developing MANF-based products as treatments for brain and ophthalmic disorders. MANF was discovered from the Company's proprietary discovery engine PhenoGuard. AMBS also received 80 million shares of Avant Diagnostics, Inc. via the sale of its wholly-owned subsidiary Amarantus Diagnostics, Inc.
Why would he do if he also part of the scheme?
Fiduciary Duties
Both the board of directors and the CEO of a small business have a fiduciary responsibility to the business's shareholders. The fiduciary duties are legal concepts that form the basis of a CEO's legal relationship with his company's owners. According to the American Bar Association, courts have ruled that a CEO's relationship with his small business's shareholders carries more legal responsibility than his relationship with his company's creditors. This is because the creditors' relationship with the company exists purely as a result of a legal contract. The shareholders' relationship with the CEO, by contrast, entails both a binding contract and the trust of that CEO in controlling the shareholders' property.
Duties of Care, Loyalty and Disclosure
A CEO's legal responsibilities to his company's shareholders are broken down into three distinct fiduciary duties: the duty of care, the duty of loyalty and the duty of disclosure. The duty of care refers to the CEO's responsibility to consider all of the available information relevant to business decisions, including the advice of experts and employees. The duty of care also includes the responsibility to understand and evaluate the company's day to day operations and the terms of agreements. The duty of loyalty requires that a CEO always acts in the best interest of a business's shareholders, and that he places that interest above his own in business decisions. This includes the responsibility to avoid conflicts of interest. Finally, the fiduciary duty of disclosure mandates that a CEO fully inform both the board of directors and the shareholders about the major issues facing the business.
0.06 the reason being...
$ / shares
Debt Instrument [Line Items]
Stated Interest Rate
12.00%
Conversion Terms | $ / shares
$ 0.05
Accumulated Debt Discount
$ (2,963)
Carrying Value
$ 2,389
Delafeild Investments Ltd [Member] | Senior Secured Convertible Promissory Notes [Member]
Debt Instrument [Line Items]
Issue Date
Sep. 30, 2015
Maturity Date
Sep. 29, 2016
Stated Interest Rate
12.00%
Conversion Terms | $ / shares
$ 0.06
Face Value
$ 3,056
Accumulated Debt Discount
(1,716)
Carrying Value
$ 1,340
Dominion Capital LLC [Member] | Senior Secured Convertible Promissory Notes [Member]
Debt Instrument [Line Items]
Issue Date
Sep. 30, 2015
Maturity Date
Sep. 29, 2016
Stated Interest Rate
12.00%
Conversion Terms | $ / shares
$ 0.06
Face Value
$ 2,096
Accumulated Debt Discount
(1,177)
Carrying Value
$ 919
GEMG LLC [Member] | Senior Secured Convertible Promissory Notes [Member]
Debt Instrument [Line Items]
Issue Date
Mar. 09, 2016
Maturity Date
Jul. 01, 2016
Stated Interest Rate
12.00%
Conversion Terms | $ / shares
$ 0.06
Face Value
$ 200
Accumulated Debt Discount
(70)
Carrying Value
$ 130
Why do you think AMBS applied for RPDD for ESS ,Nevus and Elto?.
Why do you think AMBS hired Dr.Brian Harvey?
He did the RS showing uplisting as a cause, TFs and his backdoor allies shorted all the way thru 0.029 .Now planned to RS again, to do the same again, but looks like hesitating to do that.
This CEO is irresponsible and not working in the best interests of shareholders.He agreed to short the shares as a hedge, great work of srff.The only miracle is approval of RPDD for ESS and Elto,imho.
They defaulted on the notes terms and hence conversions, imho.Dont mislead.
As otcqb certification
shares owned by GC and others.
Name
Address (City and State only)
% Shares Owned
Gerald Commissiong
Hummelstown, PA
0.15
John Commissiong
Sunnyvale, CA
0.19
Robert Harris
Oakland, CA
0.21
Joseph Rubinfeld
Blackhawk, CA
0.04
Robert Farrell
Novato, CA
0.00
Marc Faerber
Pleasanton, CA
0.01
Date: 6/6/2016
Name of Certifying CEO or CFO: Gerald Commissiong
Title: CEO
This company has IP which is not valued.But it bought the ESS and other products and raised around $40mm last year.That value should be there,though the stock price does not reflect it yet.
Biotech success stories does not happen in months, it takes time for the research and clinical trials.Its not a day trade stock imho.
Are you holding stock or buying or selling?.Are you trying to help fellow shareholders like me?.
P&A dictates the POR and GSA.Assets were transferred/assigned to JPM and WMI according to 363 sales in chapter 11.Initial payment was made of 1.9B, the final amount should be settled at the final closing date, that should happen some time soon,imho. Who saved who, is not relevant.
Do you have any court document where JPM mentioned seizing the bank was in the best interests of WMILT?